Programme

Saturday, 11 May 2019

13:30 – 15:00

Satellite Symposium UCB Biopharma
The Expedition: Exploring our understanding of the methods to predict fracture risk reduction
Chair: Serge Ferrari (Switzerland)

13:30 – 13:45

Clinical tools to assist goal-directed therapy for fragility fracture patients
Serge Ferrari (Switzerland)

13:45 – 14:25

Debate
Mass vs structure: Which measurement can help guide my patients’ therapy?
Serge Ferrari (Switzerland)
Roland Chapurlat (France)

14:25 – 14:50

How do cells translate drug effects into bone strength?
Roland Baron (United States)

14:50 – 15:00

Looking to the future
All, led by Serge Ferrari (Switzerland)

Sunday, 12 May 2019

14:45 – 16:15

Satellite Symposium Amgen (Europe) GmbH
Putting Patient Care at the Forefront of Osteoporosis Management
Chair: Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)
Bente Langdahl (Denmark)
Prieto Alhambra (United Kingdom)

14:45 – 14:50

Welcome and introduction
Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)

14:50 – 15:15

Building long term therapy into patient management
Bente Langdahl (Denmark)

15:15 – 15:40

Real world data – impact on our understanding of osteoporosis treatment
Daniel Prieto-Alhambra (United Kingdom)

15:40 – 16:05

Mechanisms of long -term effects of denosumab -on and off therapy
Serge Ferrari (Switzerland)

16:05 – 16:15

Q&A session and closing comments
Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)

Monday, 13 May 2019

14:45 – 16:15

Satellite Symposium Gedeon Richter Plc
In Conversation: Biosimilars in the Future Treatment of Osteoporosis

14:45 – 14:55

Welcome and Introduction
Eugene McCloskey (United Kingdom)

14:55 – 15:15

Biosimilars in Rheumatology in the EU – Benefits, Experiences and Practices
Julie Marechal-Jamil (Belgium)

15:15 – 15:45

Teriparatide in the Treatment Guidelines – Theory and Reality
Peyman Hadji (Germany)

15:45 – 16:00

RGB-010 Development – Concept and Results
Istvan Takacs (Hungary)

16:00 – 16:15
Q&A session and closing comments
This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.

This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.